• Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

    Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

  • Latent HHV-6B infection of astrocytes may increase the risk of depression by activating the HPA axis

    Japanese investigators show that a protein expressed by latent HHV-6B in astrocytes, results in an influx of extra-cellular calcium, triggering the onset of depression.

  • Mothers with iciHHV6 have an increased risk of spontaneous abortion

    27.6% of Japanese mothers with iciHHV6 had a spontaneous abortion compared to 14.8% of controls. iciHHV6 mothers were also 6.4X more likely to have two or more spontaneous abortions.

  • Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

    Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications

Latest Immunity & Immunotherapy Articles

View Post

Adding an adoptive NK cell infusion to naïve T-Cell-depleted grafts may reduce the rate of HHV-6B reactivation and encephalitis

A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.

View Post

Viral reactivation may be one cause of febrile neutropenia in chemotherapy patients

HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients

View Post

The effects of HHV-6B infection on immune checkpoint inhibition

HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways

View Post

HHV-6 linked to intrauterine growth restriction via the human leukocyte antigen-G dysregulation

A small study found a strong association between HHV-6 infection of the placenta and intrauterine growth restriction—a finding consistent with other evidence linking HHV-6 to several reproductive diseases.

View Post

HHV-6A and 7 infection of T cells downregulates the protein tyrosine phosphatase, CD45

CD45, important in T cell receptor signaling, may be one mechanism by which roseolaviruses evade immune detection and help achieve latency

View Post

iciHHV-6 may modulate human gene expression

A Japanese group found that ciHHV6 genes encoding for immunoglobulins were decreased in ciHHV6 individuals, possibly modulating immune responses.

View Post

HHV-6A, HHV-6B, and HHV-7 have differential impact on intracellular DNA sensors of NK cells

Cytokine and chemokine responses were very similar in HHV-6B and HHV-7 infections. The results were starkly different for HHV-6A.

View Post

49 new CD4 T-cell-recognized HHV-6B antigens identified using genome-wide approach

University of Washington investigators utilized rare cell enrichment and an HLA-agnostic, proteome-wide approach to expand the library of known HHV-6 T cell antigens from 11 to 60.

View Post

New HLA-DR3-restricted HHV-6B peptides demonstrate broadly recognized polyfunctional and cytotoxic CD4 T-cell responses

University of Massachusetts investigators have identified 25 new naturally processed peptide sequences using mass spectrometry.

View Post

HHV-6 infection induces a high percentage of virus-specific suppressive Tregs compared to CMV

A French group studied immunological responses to HHV-6 and CMV in healthy adults ex vivo and found that HHV-6 induces an excessive number of potently immunosuppressive T regulatory cells that block dendritic cell maturation and functions.

View Post

An elevated CD134/CD4+ ratio before conditioning results in a 10 fold increased risk of HHV-6B reactivation

A prospective study of allogenic stem cell transplant patients in Japan suggests that the percentage of CD134+ T cells could be used to predict which patients are vulnerable to HHV-6 reactivation. The authors propose that further investigation into the effect of elevated CD134+ T cells pre-transplant is warranted.

View Post

Breakthrough on therapeutic HHV-6B neutralizing antibodies

Yasuko Mori and colleagues were successful in humanizing two neutralizing monoclonal antibodies to HHV-6B. The chimeric antibodies performed well enough to show promise for therapeutic use.

View Post

Virus specific donor T cells found effective in treating HHV-6 and other viruses in Phase II clinical trial

“Off-the-shelf” donor T cells primed to fight five specific viruses were shown to be effective in a Phase 2 trial backed by Viracyte. A single infusion produced a complete or partial response rate of 92%.

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

Scientific News

  • Latest Scientific News

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use